Summary
75 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 16 JPY is left as net profit.
- You pay 12.2 JPY for 1 JPY of yearly profit, little for its sector.
- Revenue grew by 14% a year over the last 3 years.
- It earns 14 JPY a year on every 100 JPY of invested capital.
What to watch
- Earnings per share fell by 25% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.2 JPY for 1 JPY of yearly profit. Over the last five years it was 62.9 JPY on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 8.0% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 11%. Earnings per share fell by 25% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 JPY of revenue goes
- Cost of sales 25 JPY
- Research and development 14 JPY
- Sales and administration 39 JPY
- Taxes and other 5.8 JPY
- Net profit 16 JPY
Net profit, industry median (Drug Manufacturers - General) 14 JPY
Out of every 100 JPY of revenue, 16 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.61%
- Paid out of profit
- 20%
You receive ¥40.00 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail